Association of adipocytokines serum levels with left atrial thrombus formation in atrial fibrillation patients on oral anticoagulation (Alert) - A cross-sectional study

Autor: Thomas Deneke, Andreas Mügge, Joern Schmitt, Patrick Mueller, Fabian Schiedat, Friederike Hauffe, Christian W. Hamm, Hisaki Makimoto, Hermann Blessberger, Clemens Steinwender, Anita Meissner, Christopher Gemein, Michael Gabriel
Rok vydání: 2020
Předmět:
Leptin
Male
Time Factors
Endocrinology
Diabetes and Metabolism
Medicine (miscellaneous)
Administration
Oral
030204 cardiovascular system & hematology
Logistic regression
Body Mass Index
0302 clinical medicine
Risk Factors
Germany
Atrial Fibrillation
Clinical endpoint
Resistin
Prospective Studies
Nicotinamide Phosphoribosyltransferase
Aged
80 and over
Nutrition and Dietetics
Atrial fibrillation
Middle Aged
Stroke
Treatment Outcome
Cardiology
Cytokines
Female
Adiponectin
Cardiology and Cardiovascular Medicine
medicine.medical_specialty
Adipokine
030209 endocrinology & metabolism
Risk Assessment
03 medical and health sciences
Adipokines
Internal medicine
Multicenter trial
Thromboembolism
medicine
Humans
Thrombus
Aged
business.industry
Anticoagulants
Thrombosis
medicine.disease
Cross-Sectional Studies
business
Biomarkers
Echocardiography
Transesophageal
Zdroj: Nutrition, metabolism, and cardiovascular diseases : NMCD. 31(3)
ISSN: 1590-3729
Popis: Background and aims Oral anticoagulation is effective for stroke prevention in atrial fibrillation (AF). However, strokes may still occur in high-risk individuals. We conducted a prospective trial to assess the association between adipocytokine serum levels and surrogate parameters for thromboembolic events. Methods and results In this cross-sectional multicenter trial, we enrolled 189 patients with AF who were on oral anticoagulation. The primary endpoint was defined as either the presence of spontaneous echo contrast (SEC), a left atrial appendage (LAA), or a left atrial (LA) thrombus on transesophageal echocardiography. We investigated the association of adipocytokine serum levels with the combined endpoint using logistic regression analysis. Forty-eight individuals (25%) were assigned to group 1 (G1) due to the occurrence of at least one of the components of the combined endpoint (41 [21.7%] SEC, 3 [1.6%] LA thrombus, 13 [6.9%] LAA thrombus), whereas the remaining patients formed group 2 (G2). The BMI, logarithmized (loge) leptin (G1: 2.0 ± 1.3 μg/ml, G2: 2.0 ± 1.1 μg/ml, p = 0.746) and visfatin serum levels (G1: 3.4 ± 0.3 ng/ml, G2: 3.4 ± 0.5 ng/ml, p = 0.900) did not significantly differ between the groups. Conversely, logarithmized adiponectin (G1: 3.3 ± 0.6 ng/ml, G2: 3.1 ± 0.7 ng/ml, p = 0.036) and resistin levels (G1: 1.8 ± 0.5 ng/ml, G2: 1.6 ± 0.5 ng/ml, p = 0.009) were higher in patients with the primary endpoint. Multivariate logistic regression analysis using a score that combined the individual adiponectin and resistin values in each patient corroborated this association. Conclusions Our results suggest that adiponectin and resistin may act as potential biomarkers to identify individuals with AF who are at high thromboembolic risk.
Databáze: OpenAIRE
Externí odkaz: